// App-Quantinova.ai

2564 : First-in-human study of 4SC-205 (AEGIS), a novel oral inhibitor of Eg5 kinesin spindle protein.

Researchers

Presenter

  • Klaus B. Mross

Principal Investigators

  • Dirk Scharr

  • Heike Richly

  • Babett Krauss

  • Rolf Krauss

  • Anna Mais

  • Bernhard Hauns

  • Bernd Hentsch

  • Roland Baumgartner

  • Max E. Scheulen

  • Annette Frost

  • Sebastian Bauer

Medical Centers

  • Department of Medical Oncology, West German Cancer Center, University of Duisburg-Essen, University Hospital Essen, Essen, Germany

  • SC AG, Martinsried, GermanyNovartis, Basel, SwitzerlandKTB Klinik fuer Tumorbiologie, Freiburg, Germany

  • Department of Radiation Oncology, West German Tumor Centre, University Hospital Essen, University Duisburg-Essen, Essen, Germany

  • 4SC AG, Planegg-Martinsried, Germany

Locations

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • 4SC-205

Outcome

  • Positive

Study Design

  • pharmacokinetics

Phase

  • NA

Study Id's

  • NCT01065025

Sponsors

  • Novartis

  • 4SC AG

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved